Compare WFRD & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WFRD | BIO |
|---|---|---|
| Founded | 1941 | 1952 |
| Country | United States | United States |
| Employees | N/A | 7450 |
| Industry | Metal Fabrications | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 6.9B |
| IPO Year | 2014 | N/A |
| Metric | WFRD | BIO |
|---|---|---|
| Price | $101.87 | $243.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | $103.22 | ★ $339.75 |
| AVG Volume (30 Days) | ★ 1.2M | 320.5K |
| Earning Date | 04-21-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.49 | N/A |
| Revenue | ★ $4,331,000,000.00 | N/A |
| Revenue This Year | N/A | $2.74 |
| Revenue Next Year | $5.22 | $3.20 |
| P/E Ratio | $68.14 | ★ $9.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.75 | $211.43 |
| 52 Week High | $112.31 | $343.12 |
| Indicator | WFRD | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 46.67 | 30.25 |
| Support Level | $96.35 | N/A |
| Resistance Level | $105.55 | $289.61 |
| Average True Range (ATR) | 4.56 | 10.82 |
| MACD | -0.96 | -4.22 |
| Stochastic Oscillator | 32.71 | 1.24 |
Weatherford provides oilfield services and equipment to national, integrated, public, and private oil and gas operators. It operates across multiple upstream markets, including offshore, the rest of the world onshore, and US onshore, where Weatherford has limited exposure. The Middle East, North Africa, and Asia account for over 25% of sales. Weatherford also offers manufacturing, research, and training services. Performance is reported through three segments: drilling and evaluation, well construction and completions, and production and intervention.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.